Dr Tom Frieden, former director of CDC, referred to the Final Report of a Trial of Intensive versus Standard Blood-Pressure Control, published in May in the New England Journal of Medicine.
Conclusions:”Among patients who were at increased cardiovascular risk, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and lower all-cause mortality than targeting a systolic blood pressure of less than 140 mm Hg…”
This month I also updated by comparison of the Healthmote BT-105 and the new CardioBlip by Carrematix to our office sphygmomanometer. We are still in the process of talking with both of these companies about their products as we continue to mainly use the Healthmote system for our own RPM services.
Podcast: Play in new window | Download
Subscribe: Google Podcasts | RSS